CVA Family Office’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $12.4K | Sell |
82
-29
| -26% | -$4.4K | ﹤0.01% | 765 |
|
|
2025
Q1 | $16.7K | Buy |
111
+70
| +171% | +$10.5K | ﹤0.01% | 712 |
|
|
2024
Q4 | $7.57K | Sell |
41
-12
| -23% | -$2.22K | ﹤0.01% | 830 |
|
|
2024
Q3 | $10.4K | Sell |
53
-45
| -46% | -$8.86K | ﹤0.01% | 752 |
|
|
2024
Q2 | $20.2K | Hold |
98
| – | – | ﹤0.01% | 634 |
|
|
2024
Q1 | $26.6K | Hold |
98
| – | – | ﹤0.01% | 595 |
|
|
2023
Q4 | $23.2K | Buy |
+98
| New | +$23.2K | ﹤0.01% | 600 |
|
|
2023
Q3 | – | Sell |
-242
| Closed | -$50.9K | – | 386 |
|
|
2023
Q2 | $50.9K | Buy |
242
+144
| +147% | +$30.3K | 0.01% | 448 |
|
|
2023
Q1 | $19.8K | Hold |
98
| – | – | ﹤0.01% | 594 |
|
|
2022
Q4 | $21.4K | Hold |
98
| – | – | 0.01% | 552 |
|
|
2022
Q3 | $19K | Buy |
98
+60
| +158% | +$11.6K | 0.01% | 533 |
|
|
2022
Q2 | $8K | Sell |
38
-25
| -40% | -$5.26K | ﹤0.01% | 670 |
|
|
2022
Q1 | $18K | Sell |
63
-45
| -42% | -$12.9K | ﹤0.01% | 579 |
|
|
2021
Q4 | $41K | Buy |
108
+53
| +96% | +$20.1K | 0.01% | 393 |
|
|
2021
Q3 | $12K | Sell |
55
-68
| -55% | -$14.8K | 0.01% | 285 |
|
|
2021
Q2 | $46K | Buy |
123
+85
| +224% | +$31.8K | 0.01% | 378 |
|
|
2021
Q1 | $11K | Buy |
+38
| New | +$11K | ﹤0.01% | 508 |
|
|
2020
Q4 | – | Sell |
-55
| Closed | -$12K | – | 357 |
|
|
2020
Q3 | $12K | Buy |
+55
| New | +$12K | 0.01% | 285 |
|